Spots Global Cancer Trial Database for stage iii prostate cancer
Every month we try and update this database with for stage iii prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate | NCT00084864 | Prostate Cancer | calcitriol dexamethasone clinical observ... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | NCT01220973 | Prostate Cancer | atorvastatin ca... celecoxib laboratory biom... | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer | NCT03103321 | Stage II Prosta... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage I Prostat... PSA Level Five ... PSA Level Less ... PSA Level Ten t... | Internet-Based ... Internet-Based ... Best Practice Quality-of-Life... Questionnaire A... Survey Administ... Laboratory Biom... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer | NCT00967889 | Prostate Cancer | gene expression... protein analysi... biologic sample... laboratory biom... | - | National Cancer Institute (NCI) | |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | NCT00601406 | Breast Cancer Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... Prostate Cancer Sarcoma Vaginal Cancer Vulvar Cancer | gene expression... gene rearrangem... polymorphism an... laboratory biom... radiation thera... | - | National Cancer Institute (NCI) | |
| Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | NCT01882985 | Adenocarcinoma ... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | Docetaxel Lycopene | 21 Years - | University of California, Irvine | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer | NCT00423475 | Prostate Cancer | goserelin aceta... adjuvant therap... radiation thera... | 18 Years - 120 Years | UNICANCER | |
| Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery | NCT02144649 | Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | dietary interve... dietary interve... questionnaire a... Correlative stu... | 21 Years - | Ohio State University Comprehensive Cancer Center | |
| Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer | NCT00667069 | Prostate Cancer | triptorelin adjuvant therap... 3-dimensional c... | 18 Years - | UNICANCER | |
| Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer | NCT00027794 | Prostate Cancer | conventional su... | - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802 | NCT01672905 | Prostate Cancer | laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence | NCT00003858 | Prostate Cancer | mitoxantrone hy... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer | NCT00020995 | Prostate Cancer | therapeutic die... | 40 Years - 80 Years | National Cancer Institute (NCI) | |
| Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer | NCT00667069 | Prostate Cancer | triptorelin adjuvant therap... 3-dimensional c... | 18 Years - | UNICANCER | |
| Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00483561 | Prostate Cancer | Gefitinib plus ... | 19 Years - 120 Years | University of Nebraska | |
| Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer | NCT00551525 | Prostate Cancer | Radiotherapy Samarium 153 | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer | NCT00321698 | Prostate Cancer | Intensity-Modul... Docetaxel+IMRT | 18 Years - 100 Years | OHSU Knight Cancer Institute | |
| Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery | NCT01912820 | Adenocarcinoma ... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | green tea extra... quercetin placebo therapeutic con... laboratory biom... | 40 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer | NCT01546987 | Prostate Cancer | GnRH agonist Anti-androgen TAK-700 Radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer | NCT03963739 | Prostate Adenoc... Stage I Prostat... Stage II Prosta... Stage III Prost... | Interview Questionnaire A... | 18 Years - | Wake Forest University Health Sciences | |
| Helping African American Prostate Cancer Survivors and Their Partners Cope With Challenges After Surgery for Prostate Cancer | NCT00869739 | Cancer Survivor Depression Gastrointestina... Male Erectile D... Prostate Cancer Psychosocial Ef... Urinary Complic... | telephone-based... educational int... partner-assiste... questionnaire a... psychosocial as... quality-of-life... | - | East Carolina University | |
| GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | NCT00074022 | Recurrent Non-s... Recurrent Prost... Stage III Prost... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... Stage IV Prosta... Unspecified Adu... | GTI-2040 docetaxel laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer | NCT00670046 | Prostate Cancer | valproic acid standard of car... | 18 Years - 85 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | NCT00767286 | Prostate Cancer | flutamide goserelin aceta... low-LET cobalt-... low-LET photon ... | 50 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy | NCT00086736 | Prostate Cancer | bicalutamide eflornithine oral eflornithi... oral bicalutami... | 18 Years - | University of Alabama at Birmingham | |
| Positron Emission Tomography in Prostate Cancer | NCT00121212 | Prostate Cancer | carbon-11 aceta... | - | Washington University School of Medicine | |
| Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583 | NCT00898833 | Prostate Cancer | laboratory biom... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer | NCT00036933 | Prostate Cancer | MUC-2-Globo H-K... QS21 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors | NCT03880422 | Cancer Survivor Obesity Overweight Prostate Adenoc... Stage A Prostat... Stage B Prostat... Stage C Prostat... Stage D Prostat... Stage I Prostat... Stage II Prosta... Stage IIA Prost... Stage IIB Prost... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Dietary Interve... Educational Int... Exercise Interv... Quality-of-Life... Survey Administ... | 18 Years - | Roswell Park Cancer Institute | |
| Radiation Therapy in Treating Patients With Prostate Cancer | NCT00002480 | Prostate Cancer | radiation thera... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer | NCT00244920 | Prostate Cancer | bicalutamide leuprolide acet... squalamine lact... adjuvant therap... antiandrogen th... antiangiogenesi... conventional su... neoadjuvant the... releasing hormo... | 18 Years - | OHSU Knight Cancer Institute | |
| Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer | NCT00796458 | Pain Prostate Cancer | docetaxel releasing hormo... | 18 Years - | National Cancer Institute (NCI) | |
| Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer | NCT01023061 | Adenocarcinoma ... Stage II Prosta... Stage III Prost... Stage IV Prosta... | abiraterone ace... prednisone leuprolide acet... laboratory biom... external beam r... goserelin aceta... | 18 Years - | University of Washington | |
| Docetaxel in Treating Patients With Relapsed Prostate Cancer | NCT00482274 | Prostate Cancer | docetaxel | 18 Years - | OHSU Knight Cancer Institute | |
| Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer | NCT00996749 | Stage III Prost... | omega-3 fatty a... bone scan dual x-ray abso... laboratory biom... biopsy | 18 Years - | Wake Forest University Health Sciences | |
| Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer | NCT00345813 | Prostate Cancer | soy isoflavones soy protein iso... placebo | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | NCT01469338 | Diarrhea Hormone-resista... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | cabazitaxel prednisone octreotide pamo... questionnaire a... octreotide acet... | 18 Years - | University of Southern California | |
| Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer | NCT00054106 | Prostate Cancer | buserelin custirsen sodiu... flutamide conventional su... neoadjuvant the... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | NCT00450749 | Adenocarcinoma ... Stage I Prostat... Stage II Prosta... Stage III Prost... | placebo therapeutic con... laboratory biom... lycopene | 18 Years - | National Cancer Institute (NCI) | |
| Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer | NCT02048150 | Adenocarcinoma ... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | anti-PSMA monoc... robot-assisted ... diffuse optical... pharmacological... Laboratory Biom... Questionnaire | 36 Years - 74 Years | City of Hope Medical Center | |
| GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | NCT00074022 | Recurrent Non-s... Recurrent Prost... Stage III Prost... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... Stage IV Prosta... Unspecified Adu... | GTI-2040 docetaxel laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers | NCT00984919 | Prostate Cancer | high performanc... laboratory biom... mass spectromet... | 40 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy | NCT00086736 | Prostate Cancer | bicalutamide eflornithine oral eflornithi... oral bicalutami... | 18 Years - | University of Alabama at Birmingham | |
| Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer | NCT00849082 | Prostate Cancer | cyproterone ace... goserelin aceta... radiation thera... | - 79 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer | NCT00288080 | Prostate Cancer | Dexamethasone Prednisone docetaxel Oral antiandrog... Radiation thera... LHRH agonist | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer | NCT01243385 | Prostate Cancer | Metformin | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | NCT03477864 | Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Ipilimumab Stereotactic Bo... Radical Prostat... Anti-PD-1 Monoc... | 18 Years - | Thomas Jefferson University | |
| Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer | NCT00967889 | Prostate Cancer | gene expression... protein analysi... biologic sample... laboratory biom... | - | National Cancer Institute (NCI) | |
| Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer | NCT00989105 | Prostate Cancer | immunohistochem... laboratory biom... pharmacological... computed tomogr... magnetic resona... single photon e... technetium Tc 9... | 18 Years - | Cancer Research UK | |
| PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802 | NCT01672905 | Prostate Cancer | laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| APC8015 and Bevacizumab in Treating Patients With Prostate Cancer | NCT00027599 | Prostate Cancer | bevacizumab prostatic acid ... sipuleucel-T therapeutic aut... in vitro-treate... | - | National Cancer Institute (NCI) | |
| Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | NCT00170157 | Prostate Adenoc... Prostate Carcin... Recurrent Prost... Stage III Prost... Stage IV Prosta... | Bicalutamide Flutamide Goserelin Aceta... Ipilimumab Leuprolide Acet... Pharmacological... | 18 Years - | Mayo Clinic | |
| Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | NCT00041171 | Adult Solid Tum... Breast Cancer Head and Neck C... Kidney and Urin... Male Reproducti... Thorax and Resp... | Hypericum perfo... docetaxel placebo | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | NCT00771017 | Prostate Cancer | GVAX prostate c... bicalutamide goserelin leuprolide acet... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer | NCT00376792 | Prostate Cancer | docetaxel active surveill... adjuvant therap... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer | NCT00049309 | Prostate Cancer | dietary interve... flaxseed | 18 Years - 120 Years | Duke University | |
| Comparison of Radiation Therapy Regimens in Treating Patients With Localized Prostate Cancer | NCT00010244 | Prostate Cancer | radiation thera... | 0 Years - 74 Years | UNICANCER | |
| Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer | NCT00897793 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Prostate Cancer | venipuncture radiation thera... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Fulvestrant in Treating Patients With Advanced Prostate Cancer | NCT00244998 | Prostate Cancer | fulvestrant | 18 Years - | Roswell Park Cancer Institute | |
| Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy | NCT01656304 | Adenocarcinoma ... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | bevacizumab laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence | NCT00003858 | Prostate Cancer | mitoxantrone hy... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy | NCT01009736 | Prostate Cancer | tomato-soy juic... laboratory biom... pharmacological... therapeutic con... | - | Ohio State University Comprehensive Cancer Center | |
| EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | NCT00004261 | Breast Cancer Cervical Cancer Head and Neck C... Prostate Cancer Sarcoma | EF5 flow cytometry fluorescent ant... immunohistochem... biopsy | 18 Years - 120 Years | University Health Network, Toronto | |
| Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy | NCT01656304 | Adenocarcinoma ... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | bevacizumab laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors | NCT00433407 | Breast Cancer Lung Cancer Ovarian Cancer Prostate Cancer Sarcoma Unspecified Adu... | trastuzumab | - | Jonsson Comprehensive Cancer Center | |
| SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | NCT00026377 | Prostate Cancer | bicalutamide flutamide goserelin aceta... leuprolide acet... SU5416 radiation thera... | - | University of Chicago | |
| Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer | NCT00651326 | Prostate Cancer | bicalutamide buserelin flutamide goserelin leuprolide acet... neoadjuvant the... quality-of-life... radiation thera... Docetaxel | 18 Years - | Canadian Cancer Trials Group | |
| Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors | NCT03880422 | Cancer Survivor Obesity Overweight Prostate Adenoc... Stage A Prostat... Stage B Prostat... Stage C Prostat... Stage D Prostat... Stage I Prostat... Stage II Prosta... Stage IIA Prost... Stage IIB Prost... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Dietary Interve... Educational Int... Exercise Interv... Quality-of-Life... Survey Administ... | 18 Years - | Roswell Park Cancer Institute | |
| Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer | NCT00967954 | Prostate Cancer | antiandrogen th... releasing hormo... DNA analysis RNA analysis comparative gen... gene expression... laboratory biom... diffusion-weigh... magnetic resona... | - | National Cancer Institute (NCI) | |
| Study of a Polymorphism in Patients With Prostate Cancer | NCT00900185 | Prostate Cancer | mutation analys... polymerase chai... polymorphism an... | - | National Cancer Institute (NCI) | |
| Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | NCT00771017 | Prostate Cancer | GVAX prostate c... bicalutamide goserelin leuprolide acet... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy | NCT01555632 | Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | atorvastatin ca... placebo | 19 Years - | University of Nebraska | |
| GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer | NCT00400517 | Prostate Cancer | sargramostim thalidomide conventional su... neoadjuvant the... | - 120 Years | The Cleveland Clinic | |
| GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer | NCT00305669 | Prostate Cancer | sargramostim immunohistochem... immunological d... laboratory biom... conventional su... neoadjuvant the... | - | University of California, San Francisco | |
| Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer | NCT00103194 | Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery | NCT01079793 | Prostate Cancer | ixabepilone adjuvant therap... intensity-modul... | 18 Years - 120 Years | University of Texas Southwestern Medical Center | |
| Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer | NCT00653757 | Prostate Cancer | goserelin aceta... leuprolide acet... image-guided ra... intensity-modul... | 19 Years - | Mayo Clinic | |
| Visually Enhanced Education About Prostate Cancer | NCT02846870 | Stage I Prostat... Stage II Prosta... Stage III Prost... | Visually enhanc... Standard prosta... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery | NCT00977457 | Prostate Cancer | DNA analysis DNA methylation... RNA analysis gene expression... polymerase chai... diagnostic labo... therapeutic con... | 18 Years - | City of Hope Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
